Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media

被引:10
|
作者
Canga, Ana [1 ]
Kislikova, Maria [2 ]
Martinez-Galvez, Maria [3 ]
Arias, Mercedes [4 ]
Fraga-Rivas, Patricia [5 ]
Poyatos, Cecilio [6 ]
de Francisco, Angel L. M. [2 ]
机构
[1] Hosp Univ Marques de Valdecilla, Serv Radiodiagnost, Santander 39008, Spain
[2] Hosp Univ Marques de Valdecilla, Serv Nefrol, Santander 39008, Spain
[3] Hosp Jose Maria Morales Meseguer, Serv Radiodiagnost, Murcia, Spain
[4] Complejo Hosp Univ Vigo, Empresa Publ Serv Sanitarios, Unidad Diagnost Imagen Galaria, Pontevedra, Spain
[5] Hosp del Henares, Serv Radiodiagnost, Unidad Cent Radiodiagnost, Madrid, Spain
[6] Hosp Univ Dr Peset, Serv Radiodiagnost, Valencia, Spain
来源
NEFROLOGIA | 2014年 / 34卷 / 04期
关键词
Nephrogenic systemic fibrosis; Gadolinium; Magnetic resonance; Adverse reactions; CLINICAL SAFETY; DERMOPATHY; AGENTS; INVOLVEMENT; EXPERIENCE; DEPOSITION; DISORDER; PATIENT; RISK;
D O I
10.3265/Nefrologia.pre2014.Apr.12375
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Nephrogenic systemic fibrosis is a fibrosing disorder that affects patients with impaired renal function and is associated with the administration of gadolinium-based contrast media used in MRI. Despite being in a group of drugs that were considered safe, report about this potentially serious adverse reaction was a turning point in the administration guidelines of these contrast media. There has been an attempt to establish safety parameters to identify patients with risk factors of renal failure. The close pharmacovigilance and strict observation of current regulations, with special attention being paid to the value of glomerular filtration, have reduced the published cases involving the use of gadolinium-based contrast media. In a meeting between radiologists and nephrologists we reviewed the most relevant aspects currently and recommendations for its prevention.
引用
收藏
页码:428 / 438
页数:11
相关论文
共 50 条
  • [31] Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure
    Pieringer, Herwig
    Schumacher, Sabine
    Schmekal, Bernhard
    Gitter, Thomas
    Biesenbach, Georg
    CLINICAL KIDNEY JOURNAL, 2008, 1 (03): : 193 - 194
  • [32] Nephrogenic systemic fibrosis: Recommendations for gadolinium-based contrast use in patients with kidney disease
    Perazella, Mark A.
    Reilly, Robert F.
    SEMINARS IN DIALYSIS, 2008, 21 (02) : 171 - 173
  • [33] MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents Gadolinium Retention and Nephrogenic Systemic Fibrosis
    McDonald, Jennifer S.
    McDonald, Robert J.
    MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA, 2020, 28 (04) : 497 - +
  • [34] Strong association between the use of gadolinium-based contrast agents with nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis
    Jamboti, J.
    INTERNAL MEDICINE JOURNAL, 2007, 37 (07) : 508 - U4
  • [35] Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease and the Risk of Nephrogenic Systemic Fibrosis: Radiology In Training
    Alabousi, Mostafa
    Davenport, Matthew S.
    RADIOLOGY, 2021, 300 (02) : 279 - 284
  • [36] Response to "Will dialysis prevent the development of nephrogenic systemic: Fibrosis after gadolinium-based contrast administration?"
    Broome, Dale R.
    Cottrell, Alfred C.
    Kanal, Emanuel
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2007, 189 (04) : W234 - W235
  • [37] Nephrogenic Systemic Fibrosis (NSF) and Gadolinium-Based Contrast Agents (GBCAs). A Statistical Simulation Study
    Michel, Alexander
    Blenk, Tilo
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S84 - S84
  • [38] Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis
    Agarwal, Rajender
    Brunelli, Steven M.
    Williams, Kendal
    Mitchell, Matthew D.
    Feldman, Harold I.
    Umscheid, Craig A.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (03) : 856 - 863
  • [39] Incidence of Nephrogenic Systemic Fibrosis after Adoption of Restrictive Gadolinium-based Contrast Agent Guidelines
    Wang, Yingbing
    Alkasab, Tarik K.
    Narin, Ozden
    Nazarian, Rosalynn M.
    Kaewlai, Rathachai
    Kay, Jonathan
    Abujudeh, Hani H.
    RADIOLOGY, 2011, 260 (01) : 105 - 111
  • [40] Nephrogenic Systemic Fibrosis and Class Labeling of Gadolinium-based Contrast Agents by the Food and Drug Administration
    Yang, Lucie
    Krefting, Ira
    Gorovets, Alex
    Marzella, Louis
    Kaiser, James
    Boucher, Robert
    Rieves, Dwaine
    RADIOLOGY, 2012, 265 (01) : 248 - 253